Novartis’ targeted factor B inhibitor iptacopan has become the first oral monotherapy to be approved by the FDA for rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH). The drug, which will ...
--- Ruxoprubart (NM8074) met all clinical endpoints, offering a safe, differentiated treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH). CLEVELAND, May 19, 2025 (GLOBE NEWSWIRE) -- NovelMed is ...
New report covers Nuvectis Pharma (NASDAQ: NVCT) as the company transitions from a single-drug oncology story into a late-stage rare-disease player following its June licensing deal with Haisco ...
Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...
Iptacopan demonstrated significant hemoglobin improvements in PNH patients transitioning from anti-C5 therapies, validating its efficacy as an oral monotherapy. The safety profile of iptacopan was ...
Paroxysmal nocturnal hemoglobinuria leaves red blood cells more vulnerable to destruction. A common side effect is blood clots, known as thrombosis. This is largely preventable with medication to ...
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disease in which the immune system breaks apart the red blood cells (RBCs) in the body. The medical term for this premature rupture of RBCs is ...
Paroxysmal nocturnal hemoglobinuria (PNH) can make you more susceptible to infections. However, there are ways to mitigate the risk. Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disease ...
Ilene Weitz, MD, details a few abstracts on paroxysmal nocturnal hemoglobinuria (PNH) treatments that will be presented at ASH 2024, particularly data on danicopan as an add-on to ravulizumab or ...
With AstraZeneca’s dominance in the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) threatened by the recent approval of the first pill on the market for the condition, Novartis’ Fabhalta ...
Reporting on ASH 2025, Dr Jamile Shammo highlights long-term follow-up data for established paroxysmal nocturnal hemoglobinuria (PNH) therapies as well as novel agents and combinations targeting the ...
The FDA approved the complement C5 inhibitor crovalimab (Piasky) for treating paroxysmal nocturnal hemoglobinuria (PNH), a rare but life-threatening blood disease. Indicated for PNH in adults and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results